Publications & Evidence
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma
Lung Cancer Mutational Profile Correlates with Immune Profile
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition
Comprehensive Immune and Mutational Profile of Melanoma
Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠
The Immune-Excluded Phenotype Beyond Colorectal Cancer
Secondary Immunotherapeutic Targets In Inflamed Tumors
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
Algorithmic Prediction of Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors
NGS reveals specimen characteristics have minimal impact on immune gene expression signature
NGS reveals specimen characteristics have minimal impact on immune gene expression signature
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
